{"product_id":"ara-290-10mg","title":"ARA-290 10mg - Peptide for Inflammation \u0026 Tissue Signaling Research","description":"\u003ch3\u003eARA-290 (Cibinetide, CAS 1208243-50-8) – Molecular Mechanism of Action and Research Overview\u003c\/h3\u003e\n\u003cp\u003eARA-290, also known as cibinetide (CAS 1208243-50-8), is a synthetic 11-amino-acid linear peptide (sequence: Pyr-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser-OH; molecular formula C₅₁H₈₄N₁₆O₂₁; molecular weight 1,257.31 Da). It was engineered from the three-dimensional structure of helix B of erythropoietin (EPO). Unlike full-length recombinant human EPO, ARA-290 is non-erythropoietic and does not bind the classical EPOR homodimer associated with hematopoietic activity.\u003c\/p\u003e\n\u003cp\u003eInstead, ARA-290 selectively activates the innate repair receptor (IRR), a tissue-protective heteromeric complex composed of one EPOR subunit and the β-common receptor (βcR, CD131). The IRR is minimally expressed under baseline conditions but becomes upregulated in response to cellular stress, injury, or inflammation across multiple cell types, including neurons, endothelial cells, macrophages, and glial cells. This inducible expression profile localizes signaling activity to affected tissues.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch3\u003eMolecular Mechanism of Action (MOA)\u003c\/h3\u003e\n\u003cp\u003eLigand interaction with the IRR initiates several intracellular signaling cascades:\u003c\/p\u003e\n\u003cp\u003e• JAK2\/STAT3 and PI3K\/Akt pathways:\u003cbr\u003eAssociated with cellular survival signaling, anti-apoptotic regulation (e.g., Bcl-2\/Bax balance), and tissue-repair–related processes.\u003c\/p\u003e\n\u003cp\u003e• Anti-inflammatory signaling:\u003cbr\u003eARA-290 modulates NF-κB pathway activity, leading to reduced transcription of pro-inflammatory mediators such as TNF-α and IL-6. It also influences oxidative stress pathways by reducing reactive oxygen species (ROS), which contributes to suppression of inflammasome activation (e.g., NLRP3).\u003c\/p\u003e\n\u003cp\u003e• Immune modulation:\u003cbr\u003eResearch models indicate a shift in macrophage and microglial signaling profiles toward regulatory (M2-like) states.\u003c\/p\u003e\n\u003cp\u003e• Neurosensory signaling pathways:\u003cbr\u003ePreclinical data suggest modulation of TRPV1-related pathways and chemokine signaling (e.g., CCL2), which are associated with nociceptive and neuroimmune interactions.\u003c\/p\u003e\n\u003cp\u003eAlthough the peptide exhibits a short plasma half-life, downstream signaling effects may persist due to activation of intracellular regulatory pathways.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch3\u003ePreclinical and Clinical Research Context\u003c\/h3\u003e\n\u003cp\u003eARA-290 has been investigated primarily in experimental and early-phase clinical research models related to small-fiber neuropathy (SFN), metabolic signaling, and inflammatory conditions.\u003c\/p\u003e\n\u003cp\u003eAcross these research settings, observations include:\u003c\/p\u003e\n\u003cp\u003e• Modulation of neuropathic symptom-related endpoints\u003cbr\u003e• Changes in markers associated with nerve fiber structure and regeneration\u003cbr\u003e• Alterations in inflammatory and metabolic signaling parameters\u003cbr\u003e• Improvements in functional and quality-of-life–associated measurements in controlled study environments\u003c\/p\u003e\n\u003cp\u003eImportantly, available data originate from controlled research settings, including in vitro systems, animal models, and early-phase human studies. No completed Phase 3 trials have been reported as of 2026.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch3\u003eMetabolic and Inflammatory Research Observations\u003c\/h3\u003e\n\u003cp\u003eIn experimental models examining metabolic signaling:\u003c\/p\u003e\n\u003cp\u003e• Changes in glucose-related biomarkers have been reported\u003cbr\u003e• Modulation of inflammatory cytokine profiles has been observed\u003cbr\u003e• Endothelial and microvascular signaling pathways have been explored\u003c\/p\u003e\n\u003cp\u003eThese findings are generally interpreted within the broader context of inflammation-linked metabolic regulation rather than as direct therapeutic outcomes.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch3\u003eNeuroprotective and Cognitive Research Context\u003c\/h3\u003e\n\u003cp\u003eBeyond peripheral systems, ARA-290 has been studied in central nervous system (CNS) models due to its interaction with the innate repair receptor.\u003c\/p\u003e\n\u003cp\u003ePreclinical research includes:\u003c\/p\u003e\n\u003cp\u003e• Neuroinflammation modulation in neurodegenerative models\u003cbr\u003e• Effects on amyloid-related pathways in transgenic systems\u003cbr\u003e• Regulation of tau-associated signaling in experimental models\u003cbr\u003e• Reduced markers of neuronal stress and apoptosis in ischemic and injury models\u003c\/p\u003e\n\u003cp\u003eAdditional experimental observations:\u003c\/p\u003e\n\u003cp\u003e• Modulation of monocyte and microglial signaling\u003cbr\u003e• Changes in neuroimmune communication pathways\u003cbr\u003e• Effects on behavioral and cognitive test outcomes in controlled models\u003c\/p\u003e\n\u003cp\u003eLimited exploratory human research has examined cognitive and emotional processing, indicating subtle modulation of affective processing pathways without broad systemic effects.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch3\u003eSafety and Research Status\u003c\/h3\u003e\n\u003cp\u003eARA-290 is currently classified as an experimental research peptide.\u003c\/p\u003e\n\u003cp\u003eAvailable data from early-phase investigations suggest:\u003c\/p\u003e\n\u003cp\u003e• No activation of erythropoietic pathways\u003cbr\u003e• No consistent signals related to hematologic or cardiovascular parameters\u003cbr\u003e• Generally favorable tolerability profiles in controlled research settings\u003c\/p\u003e\n\u003cp\u003eHowever, comprehensive evaluation of long-term safety, pharmacokinetics, and broader applications requires further investigation.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch3\u003eResearch Use Context\u003c\/h3\u003e\n\u003cp\u003eAll information presented reflects published scientific literature and experimental findings.\u003c\/p\u003e\n\u003cp\u003eThis material is intended exclusively for laboratory research and scientific investigation.\u003cbr\u003e\u003c\/p\u003e","brand":"PRG","offers":[{"title":"Pre-filled Pen","offer_id":52895609913610,"sku":null,"price":215.0,"currency_code":"EUR","in_stock":true},{"title":"Vial","offer_id":52895609946378,"sku":null,"price":190.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0908\/7113\/6522\/files\/ara290_10mg.png?v=1776848054","url":"https:\/\/www.peptideregenesis.com\/products\/ara-290-10mg","provider":"PRG","version":"1.0","type":"link"}